Healthcare / Drug Manufacturers - Specialty & GenericTaiwan
$12.15
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-55.2M · quality 81.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.1%
↓Gross Margin
30.7%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.2%
FCF CAGR
—
FCF margin
-33.9%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $134.6M · net income $-58.2M · FCF $-45.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $134.6M | $134.6M | $153.6M | $162.5M | $135.5M |
| Net Income | $-58.2M | $-58.2M | $-73.5M | $-47.1M | $-79.4M |
| EBITDA | $-60.7M | $-60.7M | $-54.9M | $-20.7M | $-62.0M |
| EPS | — | — | -0.37 | -0.24 | -0.40 |
| Gross Margin | 30.7% | 30.7% | 41.7% | 41.6% | 42.1% |
| Operating Margin | -129.7% | -129.7% | -104.3% | -74.9% | -115.7% |
| Net Margin | -43.2% | -43.2% | -47.9% | -29.0% | -58.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 35.67 | 35.67 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-45.6M | $-45.6M | $-55.2M | $-60.0M | $-61.6M |
| Returns | |||||
| ROE | -3.1% | -3.1% | -3.9% | -2.4% | -4.2% |
| Valuation | |||||
| P/B | 1.29 | 1.29 | 1.78 | 2.29 | 1.98 |
| Growth & Yield | |||||
| Revenue Growth | -12.4% | -12.4% | -5.5% | 19.9% | — |
| EPS Growth | — | — | -54.2% | 40.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.37 → n/d
Residual
-18.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.